# Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

> **NCT05176080** · PHASE1,PHASE2 · TERMINATED · sponsor: **Henan Cancer Hospital** · enrollment: 46 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Famitinib
- **DRUG:** SHR6390
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT05176080
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-08
- **Primary completion:** 2024-07-03
- **Final completion:** 2024-07-03
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Investigators' decision
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176080, "Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05176080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*